A Phase IIa, Multicenter, Randomized, Double-Blind, Parallel- Group, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of Orally Administered TU2670 in Subjects with Moderate to Severe Endometriosis-Associated Pain.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Merigolix (Primary)
Indications Endometriosis; Pain
Focus Proof of concept; Therapeutic Use
Acronyms LUNA
Sponsors TiumBio

Most Recent Events

13 Aug 2024 Status changed from active, no longer recruiting to completed.
08 May 2024 Primary endpoint (overall pelvic pain) has been met as per TiumBio media release.
08 May 2024 Results published in the TiumBio Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight